My research focus is on an area termed 'Radiogenomics', which is the study of genetic factors that are associated with increased risk of developing late effects from radiotherapy used in treatment of cancer. The long term goal of this work is to develop a single nucleotide polymorphism (SNP) - based signature that can identify individual cancer patients who are at high risk of developing various normal tissue effects from their radiation treatment. Several genome-wide association studies are underway among prostate cancer cohorts in which patients are treated with radiotherapy and followed-up for several years to monitor for development of late urinary, rectal and sexual effects. The goal of these studies is to identify SNPs associated with each of these types of late radiotherapy effects and then develop risk models using these SNPs. Such models could be incorporated into clinical trials aiming to personalize radiotherapy to an individual's risk of normal tissue effects.
El Naqa I, Kerns SL, Coates J, Luo Y, Speers C, West CML, Rosenstein BS, Ten Haken RK. "Radiogenomics and radiotherapy response modeling." Physics in medicine and biology.. 2017 Aug 1; 62(16):R179-R206. Epub 2017 Aug 01.
Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB, . "Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2017 Apr 10; 35(11):1211-1222. Epub 2017 Feb 27.
Oh JH, Kerns S, Ostrer H, Powell SN, Rosenstein B, Deasy JO. "Computational methods using genome-wide association studies to predict radiotherapy complications and to identify correlative molecular processes." Scientific reports.. 2017 Feb 24; 7:43381. Epub 2017 Feb 24.
View All Publications